We examined the sustainability of the intraocular pressure (IOP)-lowering efficacy of travoprost (0.004%) ophthalmic solution in subjects with normal tension glaucoma (NTG). Methods: Travoprost ophthalmic solution was given once daily at 9 PM to subjects with newly diagnosed NTG or with NTG who had not received any ocular hypotensives within the previous 30 days. IOP was measured at three time points (9 AM, 1 PM, and 5 PM) at baseline and week 12 visits, and at one time point (9 AM) at week 4 and week 8 visits. Conjunctival hyperemia, superficial punctate keratopathy, and other adverse events were evaluated during the observation period.
INTRODUCTION
The Tajimi epidemiological study reported that the prevalence of glaucoma in those aged 40 years and older in Japan is 5%, and primary open-angle glaucoma accounts for 78% of the patients; more than 90% of these glaucoma patients were diagnosed as normal tension glaucoma (NTG) [1, 2] . Currently, the only proven treatment for glaucoma is to lower intraocular pressure (IOP), the major risk factor for progression of glaucomatous visual field damage [3] [4] [5] . It has been reported that a similar correlation between decreased IOP and progression of visual field defect has been noted for NTG [6] . In cases with NTG, as an initial treatment, it is recommended that IOP be lowered by 20% from baseline [7] , since this level of IOP reduction prevents progression of a visual field defect during long-term follow-up [7, 8] . Other than IOP level, IOP fluctuations defined as the differences between maximum and minimum IOP levels during follow-up periods may be another risk factor for visual field defects [9, 10] even in NTG [8] .
Minimization of IOP fluctuations may therefore be clinically important.
Patients with NTG are usually treated with topical medication(s) to lower IOP. Among currently available ocular hypotensives, prostaglandin (PG) analogs are the first-line choice of agent for the treatment of NTG because of their strong IOP-lowering effect [11] and their benefits of compliance with fewer systemic side effects and less frequent dosing.
Once-daily administration of PG analogs is based on their sustainability of IOP-lowering effect for almost an entire day. Sustained efficacy of PGs over more than 24 h may minimize the IOP fluctuation even if the daily administration time may differ to some degree. Travoprost ophthalmic solution, one of four currently available PG ocular hypotensives in Japan, was reported to have an IOP-lowering effect equal to or even superior than 0.005% latanoprost eye drops (Xalatan Ò ; Pfizer, New York, NY, USA) [12] . Other reports have shown that travoprost ophthalmic solution has an effect of sustainable IOP reduction for 24 h or longer [13] [14] [15] [16] [17] , and is thus expected to lessen IOP fluctuations. However, to date, only a few single-site studies have investigated the IOP-lowering effects of travoprost in respect to its sustainability and IOP fluctuation [11, 18, 19] . We therefore conducted multi-centered studies in subjects with Japanese NTG patients. Ocular hypotensives can affect the ocular surface mainly because of their preservative agent benzalkonium chloride (BAC) [20] .
A BAC-free formulation of travoprost, Travatan Z Ò (0.004% travoprost ophthalmic solution;
Alcon Laboratories, Inc., Fort Worth, TX, USA) [21] , contains a zinc-based self-preservation system (sofZia TM ; Alcon Laboratories, Inc., Fort Worth, TX, USA), which would be expected to have a minimal effect on the ocular surface [20] .
To verify this, we assessed ocular adverse events including superficial punctate keratopathy (SPK) and conjunctiva hyperemia following treatment with travoprost 0.004% in subjects with newly diagnosed NTG.
METHODS

Subjects
We enrolled 32 outpatients from six institutions The inclusion criteria included: (1) age 20 years or more at the time of written informed consent obtained, (2) all IOPs measured at 9 AM, 1 PM, and 5 PM within the range of[10 and\20 mmHg in the study eye at baseline, (3) either male or female. There were no specific criteria regarding outpatient/inpatient treatment history. The exclusion criteria included: (1) pregnancy (or women who wished to become pregnant during the study period) or lactation, (2) angle grade in Shaffer classification of 2 or less, (3) advanced glaucoma with the visual field mean deviation of less than -12 dB, (4) history of chronic or recurrent uveitis, scleritis, or herpes keratitis, (5) history of ocular trauma, intraocular surgery, or laser surgery in the study eye, (6) ocular infection or other ocular pathology other than glaucoma,
best-corrected visual acuity of\0.2, (8) difficulty in conducting applanation tonometry in the study eye, (9) history of hypersensitivity to PG analogs or any ingredients used in the study, (10) requirement for IOP-lowering drug(s) other than 0.004% travoprost ophthalmic solution, or oral carbonic anhydrase inhibitor during the study period, (11) requirement for any steroid therapy during the study period, (12) subjects who had received IOP-lowering ophthalmic solution within the past 30 days, or (13) subjects regarded as inappropriate for study enrollment as judged by the investigators. If both eyes were eligible, the study eye was determined as the eye with higher IOP at 9 AM of baseline. If bilateral IOP values were the same at 9 AM, the eye with higher IOP at 1 PM of baseline was defined as the study eye. If bilateral IOP values were the same at 1 PM, the eye with higher IOP at 5 PM of baseline was defined as the study eye. If all IOP values at 9 AM, 1 PM, and 5 PM of baseline were equal, the right eye was defined as the study eye.
Procedures
Before starting the study, Alcon Japan Ltd. Laboratories, Inc., Fort Worth, TX, USA) into the conjunctival sac at 9 PM, once daily for 12 weeks. On each visit at week 4, 8, and 12 after starting therapy, IOP was measured and the degrees of SPK and conjunctival hyperemia were examined, and subjects were then interviewed regarding the presence of side effects. The same investigator at each institution measured IOP twice with a Goldmann applanation tonometer; the mean IOP of two measurements was used for the analyses. At baseline and week 12, IOP was measured at three time points: at 9 AM, 1 PM, and 5 PM, and at weeks 4 and 8, IOP was measured at 9 AM. For each measurement, a range of ±30 min from the scheduled time was allowed. Throughout the study period, the same investigator measured IOP for each subject. For evaluation of SPK, the cornea was stained with fluorescein and observed with a slitlamp microscope. The National Eye Institute grid [22] was used to grade corneal staining in each of five zones (superior, temporal, inferior, nasal, and central) with a five-point scale (0-4) [23] . The mean SPK score was obtained by averaging scores among the five zones. Conjunctival hyperemia was scored according to four grades: 0, no vasodilatation; 1, vasodilation of mainly small blood vessels; 2, vasodilation of both large and small blood vessels; 3, marked vasodilation including both large and small blood vessels [24] . Reference photographs were used to grade the SPK and hyperemia. Periocular changes including eyelash, pigmentation, and sunken eyelid as compared with baseline were scored by 3-point categorical rating; scores 0 (not present), 1 (mild), and 2 (apparent). If at least one SPK score of five zones was rated as 3 or more, or the conjunctival hyperemia score was rated 3, this was reported as an adverse event. Clinically significant findings also were reported as an adverse event at any time for any medical reason at the discretion of investigators.
Statistical Analyses
In the study protocol, the effective sample size was set at 29 to detect 2.5 mmHg IOP reduction with 90% power and two-sided 5% alpha by Data are shown as mean ± standard deviation, range (min-max), unless otherwise stated dB decibels, IOP intraocular pressure, MD mean deviation, PSD pattern standard deviation summarized in Table 2 . For further clarification, the diurnal IOPs at baseline and week 12 are also shown in Fig. 1 (PPS: At 9 AM, IOP was reduced by 3.1 mmHg from baseline when the IOPs measured at weeks 4, 8, and 12 were pooled, P\0.0001). We further analyzed the diurnal fluctuations in IOPs before and after travoprost treatment (Fig. 2) . The diurnal IOP fluctuation of 2.2 ± 1.4 mmHg (mean ± SD) at baseline was reduced to 1.6 ± 0.9 mmHg at week 12 (P = 0.0333, t test), indicating a 0.6 ± 1.5 mmHg reduction.
Analysis of the safety data set showed that SPK scores did not deteriorate at any visits after the start of travoprost (Table 4) ; the maximum score reported in each corneal zone was 2 among the study eyes. Compared with the baseline value (0.3 ± 0.5), conjunctival hyperemia scores were statistically higher at weeks 4 (0.6 ± 0.6, P = 0.0169) and 12 (0.6 ± 0.7, P = 0.0323). However, 21 (70.0%) of the subjects did not have an increase in their score from the baseline value during the study period; no study eye was associated with an adverse event (score 3 or higher; Table 5 ). The changes in eyelash scores from baseline The supportive measurements outcomes were DIOP at 9 AM at week 4, week 8, and week 12, and change rates from baseline (%DIOP) at 1 PM and 5 PM at week 12. The DIOPs showed IOP reduction (P\0.0001) at any point, and the %DIOP were -19.2% and -17.9% at 1 PM and 5 PM at week 12. These results are consistent with those of a study involving NTG patients that was conducted at a single site [17] [18] [19] 26] . In our study, which was a multi-center trial, IOP was measured three times during the day, and the results suggest that travoprost may also decrease IOP throughout the day.
As the diurnal IOP fluctuated, differences between maximum and minimum IOP values at 9 AM, 1 PM, and 5 PM at baseline and at week 12 were determined. Compared with baseline, 20 subjects had decreases in the diurnal IOP variability and 10 were unchanged or had increased diurnal IOP variability at week 12.
All of the latter subjects with baseline diurnal fluctuation of 2.0 mmHg or less had unchanged or increased diurnal IOP changes, while the subjects with baseline fluctuation of 3.0-6.5 mmHg had decreased values.
According to some studies, the greater the IOP fluctuates throughout the day, the faster glaucoma progresses [9] . This study suggests that treatment with travoprost may suppress the diurnal IOP change in subjects with greater diurnal IOP variations. However, further study of diurnal IOP variations throughout a 24-h period is warranted.
We have observed conjunctival hyperemia as one of the most common side effects of PG analogs. Compared with baseline, the conjunctive hyperemia score was elevated at weeks 4, 8, and 12. However, the mean score had been 1 (minimum level) or less through the study period and no conjunctival hyperemia was reported as an adverse event.
The fluorescein staining scores of all five corneal zones at baseline in the included eyes were 0.7 ± 1.3 in total. The total SPK scores of the five areas were 0.7 ± 1.3, 0.4 ± 0.7, and 0.6 ± 1.1 at weeks 4, 8, and 12, respectively, and showed no elevated scores at any point. BAC is the most commonly used preservative in ophthalmic solutions for glaucoma therapy.
However, travoprost 0.004% does not contain BAC, but a zinc-containing self-preservation system (sofZia), that contains zinc chloride. Our findings indicate that travoprost 0.004% did not negatively affect the cornea.
The periocular scores for the change of eyelash, pigmentation, and sunken eyelids at week 12 were 0.3 ± 0.5, 0.1 ± 0.3, and 0.1 ± 0.3, respectively; the least favorable score for each item was 1.0. Although a significant change was not observed at week 12, continuous monitoring is advisable because medication is used long term in the treatment of glaucoma. Disclosures. Tomoko Naito has received lecture fees from Alcon Japan Ltd, Pfizer Japan Inc., Senju Pharmaceutical Co., Ltd, Santen Pharmaceutical Co., Ltd, and NIDEK Co., Ltd.
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